Univariate Analysis | Multivariate Analysis | ||||||
---|---|---|---|---|---|---|---|
Female | Male | p | p | Odds Ratio | 95% CI | ||
n | 138 | 23 | |||||
Age (years) | 59.3 ± 14.7 | 63.9 ± 11.8 | 0.162* | ||||
Disease duration (years) | 7.7 ± 8.2 | 4.2 ± 2.8 | 0.049* | ||||
Steroid dosage (mg/d) | 2.9 ± 3.1 | 5.0 ± 3.4 | 0.005* | 0.124 | 1.189 | 0.954-1.482 | |
MTX dosage (mg/w) | 8.2 ± 4.0 | 5.8 ± 4.4 | 0.011* | 0.118 | 0.866 | 0.724-1.037 | |
Infliximab | 50 | 4 | 0.42** | ||||
Etanercept | 14 | 7 | |||||
Adalimumab | 24 | 6 | |||||
Golimumab | 6 | 0 | |||||
Tocilizumab | 28 | 2 | |||||
Abatacept | 17 | 3 | |||||
SDAI | 22.1 ± 11.9 | 27.9 ± 11.7 | 0.036* | ||||
mHAQ | 0.46 ± 0.50 | 0.59 ± 0.48 | 0.257* | ||||
HAM-D | 6.2 ± 4.8 | 5.8 ± 4.3 | 0.724* | ||||
HAM-D>7 | 31 (22.5%) | 1 (4.3%) | 0.045*** | 0.011 | 0.041 | 0.004-0.486 | |
SF-36 | Physical functioning | 29.3 ± 17.6 | 25.8 ± 17.7 | 0.335* | |||
Role function (physical) | 31.9 ± 16.1 | 28.7 ± 15.6 | 0.385* | ||||
Pain | 35.6 ± 9.1 | 33.2 ± 8.6 | 0.252* | ||||
General health perception | 39.0 ± 9.1 | 34.8 ± 8.1 | 0.040* | ||||
Fatigue | 43.2 ± 11.5 | 41.2 ± 10.9 | 0.426* | ||||
Social functioning | 40.3 ± 14.7 | 36.4 ± 15.7 | 0.254* | ||||
Role function (emotional) | 38.9 ± 16.3 | 33.8 ± 16.4 | 0.171* | ||||
Mental health | 46.6 ± 11.2 | 39.2 ± 11.1 | 0.005* | 0.006 | 0.895 | 0.826-0.968 |